Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001104659-20-029716)

Filing Details

Accession Number:
0001104659-20-029716
Form Type:
13G Filing
Publication Date:
2020-03-05 16:13:32
Filed By:
Samsara Biocapital, L.p.
Company:
Viracta Therapeutics Inc. (NASDAQ:VIRX)
Filing Date:
2020-03-05
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Samsara BioCapital 0 5,938,215 0 5,938,215 5,938,215 5.3%
Samsara BioCapital GP 0 5,938,215 0 5,938,215 5,938,215 5.3%
Srinivas Akkaraju 0 5,938,215 0 5,938,215 5,938,215 5.3%
Filing

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

SCHEDULE 13G
(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No. )*

 

Sunesis Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

 

867328700

(CUSIP Number)

 

December 5, 2019

(Date of Event Which Requires Filing of This Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o            Rule 13d-1(b)

 

x           Rule 13d-1(c)

 

o            Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP NO. 810648 105

13 G

 

 

 

1

NAMES OF REPORTING PERSONS.
Samsara BioCapital, L.P.

 

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

 

(a)

o

 

 

(b)

x (1)

 

 

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by Each
Reporting
Person
With

5

SOLE VOTING POWER
0

 

6

SHARED VOTING POWER
5,938,215 shares(2)

 

7

SOLE DISPOSITIVE POWER
0

 

8

SHARED DISPOSITIVE POWER
5,938,215 shares(2)

 

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,938,215 shares(2)

 

 

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*  o

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.3%(3)

 

 

12

TYPE OF REPORTING PERSON*
PN

 

(1) This Schedule 13G is filed by Samsara BioCapital, L.P. (Samsara LP), Samsara BioCapital GP, LLC (Samsara GP) and Srinivas Akkaraju (and together with Samsara LP and Samsara GP, the Reporting Persons).  The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

 

(2) These shares are held by Samsara LP.  Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP.  Srinivas Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.  The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 5, 2019.

 

(3) This calculation is based upon 111,320,000 Common Shares outstanding as of November 5, 2019, as reported on the Issuers 10-Q filed with the SEC on November 12, 2019.

 

2

 

 

1

NAMES OF REPORTING PERSONS.
Samsara BioCapital GP, LLC

 

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

 

(a)

o

 

 

(b)

x (1)

 

 

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by Each
Reporting
Person
With

5

SOLE VOTING POWER
0

 

6

SHARED VOTING POWER
5,938,215 shares(2)

 

7

SOLE DISPOSITIVE POWER
0

 

8

SHARED DISPOSITIVE POWER
5,938,215 shares(2)

 

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,938,215 shares(2)

 

 

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*  o

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.3%(3)

 

 

12

TYPE OF REPORTING PERSON*
OO

 

(1) This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

 

(2) These shares are held by Samsara LP.  Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP.  Srinivas Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.  The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 5, 2019.

 

(3) This calculation is based upon 111,320,000 Common Shares outstanding as of November 5, 2019, as reported on the Issuers 10-Q filed with the SEC on November 12, 2019.

 

3

 

 

1

NAMES OF REPORTING PERSONS.
Srinivas Akkaraju

 

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

 

(a)

o

 

 

(b)

x (1)

 

 

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America

 

 

 

Number of
Shares
Beneficially
Owned by Each
Reporting
Person
With

5

SOLE VOTING POWER
0

 

6

SHARED VOTING POWER
5,938,215 shares(2)

 

7

SOLE DISPOSITIVE POWER
0

 

8

SHARED DISPOSITIVE POWER
5,938,215 shares(2)

 

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,938,215 shares(2)

 

 

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*  o

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.3%(3)

 

 

12

TYPE OF REPORTING PERSON*
IN

 

(1) This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

 

(2) These shares are held by Samsara LP.  Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP.  Srinivas Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.  The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 5, 2019.

 

(3) This calculation is based upon 111,320,000 Common Shares outstanding as of November 5, 2019, as reported on the Issuers 10-Q filed with the SEC on November 12, 2019.

 

4

 

 

Introductory Note: This Statement on Schedule 13G (this Statement) is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value $0.0001 per share (Common Stock), of Sunesis Pharmaceuticals, Inc. (the Issuer).

 

Item 1

 

(a)

Name of Issuer:

Sunesis Pharmaceuticals, Inc.

 

 

 

 

Address of Issuers Principal Executive Offices:

395 Oyster Point Boulevard

 

 

Suite 400

 

 

South San Francisco, CA 94080

 

Item 2

 

(a)

Name of Person(s) Filing:

 

 

 

Samsara BioCapital, L.P. (Samsara LP)

 

 

Samsara BioCapital GP, LLC (Samsara GP)

 

 

Srinivas Akkaraju

 

 

 

 

(b)

Address of Principal Business Office:

c/o Samsara BioCapital, LLC

 

 

628 Middlefield Road

 

 

Palo Alto, CA 94301

 

 

 

(b)

Citizenship:

 

 

 

 

 

 

Entities:

Samsara LP

-

Delaware

 

 

Samsara GP

-

Delaware

 

 

 

 

 

 

Individuals:

Srinivas Akkaraju

-

United States of America

 

 

 

 

 

(d)

Title of Class of Securities:

 

Common Stock

 

 

 

 

(e)

CUSIP Number:

 

867328700

 

 

 

 

Item 3

Not applicable.

 

 

 

5

 

Item 4

Ownership.

 

The following information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 5, 2019:

 

Reporting Persons

 

Shares Held
Directly

 

Sole Voting
Power

 

Shared
Voting
Power

 

Sole
Dispositive
Power

 

Shared
Dispositive
Power

 

Beneficial
Ownership

 

Percentage
of Class (1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Samsara LP

 

5,938,215

 

0

 

5,938,215

 

0

 

5,938,215

 

5,938,215

 

5.3

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Samsara GP

 

0

 

0

 

5,938,215

 

0

 

5,938,215

 

5,938,215

 

5.3

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Srinivas Akkaraju

 

0

 

0

 

5,938,215

 

0

 

5,938,215

 

5,938,215

 

5.3

%

 

 

(1) This calculation is based upon 111,320,000 Common Shares outstanding as of November 5, 2019, as reported on the Issuers 10-Q filed with the SEC on November 12, 2019.

 

Item 5

Ownership of Five Percent or Less of a Class.

 

 

 

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

 

 

Item 6

Ownership of More Than Five Percent on Behalf of Another Person.

 

 

 

See Items 2(a) and 4.

 

 

Item 7

Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

 

 

 

Not applicable.

 

 

Item 8

Identification and Classification of Members of the Group.

 

 

 

Not applicable.

 

 

Item 9

Notice of Dissolution of Group.

 

 

 

Not applicable.

 

 

Item 10

Certification.

 

 

By signing below, each of the undersigned certifies that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

6

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: March 5, 2020

 

 

Samsara BioCapital, L.P.

 

 

 

 

By:

Samsara BioCapital GP, LLC

 

 

its General Partner

 

 

 

 

 

 

 

By:

/s/ Srinivas Akkaraju

 

 

Name: Srinivas Akkaraju

 

 

Title: Managing Member

 

 

 

 

 

 

 

Samsara BioCapital GP, LLC

 

 

 

 

 

 

 

By:

/s/ Srinivas Akkaraju

 

 

Name: Srinivas Akkaraju

 

 

Title: Managing Member

 

 

 

 

 

 

 

 

/s/ Srinivas Akkaraju

 

 

Srinivas Akkaraju

 

 

7

 

Exhibit(s):

 

A - Joint Filing Statement

 

8

 

EXHIBIT A

 

JOINT FILING STATEMENT

 

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Sunesis Pharmaceuticals, Inc. is filed on behalf of each of us.

 

Dated: March 5, 2020

 

 

Samsara BioCapital, L.P.

 

 

 

 

By:

Samsara BioCapital GP, LLC

 

 

its General Partner

 

 

 

 

 

 

 

By:

/s/ Srinivas Akkaraju

 

 

Name: Srinivas Akkaraju

 

 

Title: Managing Member

 

 

 

 

 

 

 

Samsara BioCapital GP, LLC

 

 

 

 

 

 

 

By:

/s/ Srinivas Akkaraju

 

 

Name: Srinivas Akkaraju

 

 

Title: Managing Member

 

 

 

 

 

 

 

 

/s/ Srinivas Akkaraju

 

 

Srinivas Akkaraju

 

 

9